Abeona Therapeutics Announces Phase 3 VIITAL Study Met Two Co-Primary Efficacy Endpoints
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met
Co-primary endpoint measuring pain reduction at six